Protective effect of curcumin against rotenone-induced substantia nigra pars compacta neuronal dysfunction. 2022

L V Darbinyan, and K V Simonyan, and L E Hambardzumyan, and L P Manukyan, and S H Badalyan, and V H Sarkisian
Sensorimotor Integration Laboratory, Orbeli Institute of Physiology NAS RA, 0028, Yerevan, Armenia.

Rotenone is involved in the degeneration of dopaminergic neurons, and curcumin may prevent or effectively slow the progression of Parkinson's disease (PD). Previous research has shown that the naturally occurring phenolic compound curcumin can reduce inflammation and oxidation, making it a potential therapeutic agent for neurodegenerative diseases. The present study involves investigation of rotenone-induced histological changes in the brain area, hippocampus using Nissl staining after 35 day of subcutaneous injection of rotenone in adult male rats. We sought to determine whether curcumin could protect against rotenone-induced dopaminergic neurotoxicity in a rat model by in vivo electrical recording from Substantia nigra pars compacta (SNc). Curcumin treatment significantly improved electrical activity of neurons in the SNc of rotenone-induced PD model rats. The pattern of histological alterations corresponds with electrophysiological manifestations.

UI MeSH Term Description Entries
D008297 Male Males
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D003474 Curcumin A yellow-orange dye obtained from tumeric, the powdered root of CURCUMA longa. It is used in the preparation of curcuma paper and the detection of boron. Curcumin appears to possess a spectrum of pharmacological properties, due primarily to its inhibitory effects on metabolic enzymes. 1,6-Heptadiene-3,5-dione, 1,7-bis(4-hydroxy-3-methoxyphenyl)-, (E,E)-,Curcumin Phytosome,Diferuloylmethane,Mervia,Turmeric Yellow,Phytosome, Curcumin,Yellow, Turmeric
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012402 Rotenone A botanical insecticide that is an inhibitor of mitochondrial electron transport.
D013378 Substantia Nigra The black substance in the ventral midbrain or the nucleus of cells containing the black substance. These cells produce DOPAMINE, an important neurotransmitter in regulation of the sensorimotor system and mood. The dark colored MELANIN is a by-product of dopamine synthesis. Nigra, Substantia,Nigras, Substantia,Substantia Nigras
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus
D059290 Dopaminergic Neurons Neurons whose primary neurotransmitter is DOPAMINE. Dopamine Neurons,Dopamine Neuron,Dopaminergic Neuron,Neuron, Dopamine,Neuron, Dopaminergic,Neurons, Dopamine,Neurons, Dopaminergic
D065842 Pars Compacta A region in the substantia nigra located dorsal to the PARS RETICULATA. Substantia Nigra Compacta,Substantia Nigra Pars Compacta,Nigra Compacta, Substantia,Nigra Compactas, Substantia,Pars Compactas,Substantia Nigra Compactas

Related Publications

L V Darbinyan, and K V Simonyan, and L E Hambardzumyan, and L P Manukyan, and S H Badalyan, and V H Sarkisian
June 1986, Neuroscience letters,
L V Darbinyan, and K V Simonyan, and L E Hambardzumyan, and L P Manukyan, and S H Badalyan, and V H Sarkisian
January 1979, The Japanese journal of physiology,
L V Darbinyan, and K V Simonyan, and L E Hambardzumyan, and L P Manukyan, and S H Badalyan, and V H Sarkisian
November 2006, The Journal of neuroscience : the official journal of the Society for Neuroscience,
L V Darbinyan, and K V Simonyan, and L E Hambardzumyan, and L P Manukyan, and S H Badalyan, and V H Sarkisian
January 2009, Journal of neural transmission. Supplementum,
L V Darbinyan, and K V Simonyan, and L E Hambardzumyan, and L P Manukyan, and S H Badalyan, and V H Sarkisian
January 2017, Experimental neurology,
L V Darbinyan, and K V Simonyan, and L E Hambardzumyan, and L P Manukyan, and S H Badalyan, and V H Sarkisian
July 1973, Science (New York, N.Y.),
L V Darbinyan, and K V Simonyan, and L E Hambardzumyan, and L P Manukyan, and S H Badalyan, and V H Sarkisian
December 2006, Behavioral neuroscience,
L V Darbinyan, and K V Simonyan, and L E Hambardzumyan, and L P Manukyan, and S H Badalyan, and V H Sarkisian
September 2022, Biomedicines,
L V Darbinyan, and K V Simonyan, and L E Hambardzumyan, and L P Manukyan, and S H Badalyan, and V H Sarkisian
March 1988, Neuroscience letters,
L V Darbinyan, and K V Simonyan, and L E Hambardzumyan, and L P Manukyan, and S H Badalyan, and V H Sarkisian
February 2011, Journal of neurochemistry,
Copied contents to your clipboard!